3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $19
HC Wainwright & Co. analyst Douglas Tsao maintains Radius Health (NASDAQ:RDUS) with a Neutral and lowers the price target from $25 to $19.
SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $26
SVB Leerink analyst Geoffrey Porges maintains Radius Health (NASDAQ:RDUS) with a Market Perform and raises the price target from $24 to $26.
Radius Health Q2 EPS $(0.22) Beats $(0.33) Estimate, Sales $51.80M Up From $50.11M YoY
Radius Health (NASDAQ:RDUS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.33) by 33.33 percent. This is a 67.16 percent increase over losses of $(0.67) per share from the
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
Radius Health Publishes Study Titled ‘RWE Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women’ To ClinicalTrials.Gov, Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT04974723
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen’s Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.